Latest News

  • KALBE EDUCATES THE EFFECT OF COVID-19 SPREAD ON CONTROL OF K3 MANAGEMENT DURING EMERGENCY PPKM

    Wednesday, July 21, 2021
    KALBE EDUCATES THE EFFECT OF COVID-19 SPREAD ON CONTROL OF K3 MANAGEMENT DURING EMERGENCY PPKM

    Jakarta, July 21, 2020, PT Kalbe Farma Tbk (Kalbe) in collaboration with APINDO (Indonesian Employers Association) and Apindo Training Center (PT Pusat Studi Apindo) supported by the government through the BPJS Ketenagakerjaan (Employment) & BPJS Kesehatan (Healthcare), held an Industrial Relations Innovation Insight educational webinar with the theme "Updated Covid-19 Variants & Vaccination, and K3 Management Control during the Implementation of Emergency PPKM" with speakers: dr. Muhammad Syahril Mansyur Sp.P, MPH - President Director of RSPI Sulianti Saroso, Jakarta & Interim President Director of RS Persahabatan, Jakarta;  dr. Esther Kristiningrum – Senior Medical Manager of PT Kalbe Farma Tbk.; dr. Rima Melati, MKK, SpAk, SpOk  – Member of the K3 Committee of Apindo ; Iftida Yasar, S.H., M.Psi - Supervisory Board of BPJS Kesehatan; and Subchan Gatot - Supervisory Board of BPJS Ketenagakerjaan; with moderator Dr.  Soeprayitno, MBA.,MSc. – Director of PT. Pusat Studi Apindo (ATC).

  • GET BPOM APPROVAL, KALBE IMPLEMENT CLINICAL TRIAL COVID-19 VACCINE GX-19N

    Friday, July 9, 2021
    GET BPOM APPROVAL, KALBE IMPLEMENT CLINICAL TRIAL COVID-19 VACCINE GX-19N

    Jakarta, July 9, 2021. PT Kalbe Farma Tbk (“Kalbe”) has received approval from the Food and Drug Supervisory Agency (“BPOM”) to conduct a phase 2b/3 clinical trial for the COVID-19 GX-19N vaccine in Indonesia. The clinical trial phase 2b/3 will start recruitment in July 2021 and is expected to have enough data to carry out an interim analysis for safety and efficacy (the ability of the vaccine to trigger immunity against COVID-19 infection) by end of 2021.

  • RT-LAMP SALIVA, HELP EXPEDITE COVID-19 TESTING IN RURAL AREAS

    Monday, July 5, 2021
    RT-LAMP SALIVA, HELP EXPEDITE COVID-19 TESTING IN RURAL AREAS

    Jakarta, July 5, 2021, PT Kalbe Farma Tbk (Kalbe).  The increase in positive cases of COVID-19 in various regions in Indonesia has encouraged the government through the Ministry of Health to strengthen the implementation of 3T, namely Testing, Tracing, and Treatment. Testing, apart from screening, is also very necessary for tracking or tracing so that suspects and close contacts of confirmed cases can be found. Under the circumstances, Kalbe is trying to support the government, especially regional governments, by providing the infrastructure for testing the SARS-CoV-2 virus using the RT-LAMP Saliva examination method. The RT-LAMP method which is a biomolecular examination is categorized as the NAAT (Nucleic Acid Amplification Test) test in which the RT-PCR is of the same category.

  • SUPPORTING COVID-19 TESTS, KALBE OFFERS THE RT LAMP SALIVA TEST

    Wednesday, June 30, 2021
    SUPPORTING COVID-19 TESTS, KALBE OFFERS THE RT LAMP SALIVA TEST
    Jakarta, June 30, 2021, PT Kalbe Farma Tbk (Kalbe). The increase of COVID-19-positive numbers on daily basis has prompted Kalbe to continue innovating to assist the government in conducting the COVID-19 tests.  To increase the number of the COVID-19 tests, Kalbe through its subsidiary, KalGen Innolab, offers the innovation of COVID-19 tests by using the RT Lamp Saliva method or using saliva as samples.
RSS
12345Last